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Purpose: The purpose of this study was to evaluate the safety and efficacy of intravitreal
ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to
pathologic myopia.
Methods: This was a prospective, multicenter, consecutive, nonrandomized, interven-
tional case series. The study included 34 eyes of 32 patients with choroidal neovascular-
ization secondary to pathologic myopia; 13 eyes had previous photodynamic therapy, and
21 eyes had no previous treatment. The patients were followed for 12 months. Best-
corrected visual acuity, optical coherence tomography, and the presence of metamor-
phopsia were assessed monthly.
Results: Mean visual acuity improved 8 letters from baseline to 12-month follow-up,
and the difference was statistically significant (P  0.001): 100% of the eyes lost 3 lines
on the Early Treatment Diabetic Retinopathy Study chart, 24% of the eyes improved 3
lines, 44% improved2 lines, 65% improved1 line, and 79% improved0 lines. Central
retinal thickness decreased significantly from baseline to the 12-month follow-up (P 
0.01). A mean of 3.6 treatments were performed during the 12-month follow-up, and no
systemic or ocular side effects were registered during that time.
Conclusion: One-year results of intravitreal ranibizumab for myopic choroidal neovas-
cularization are very promising. Additional prospective studies are necessary to better
determine long-term efficacy and safety.
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A lthough the natural course of myopic choroidalneovascularization (CNV) is highly variable, the
long-term prognosis is known to be poor.1–4 Photody-
namic therapy (PDT) with verteporfin, the only treat-
ment approved by regulatory authorities in Europe, for
subfoveal myopic CNV5,6 has also shown good effi-
cacy in juxtafoveal lesions.7
However, in the verteporfin in PDT study,5 a loss of
15 letters in visual acuity was observed in up to 13%
of the treated eyes at 1 year of follow-up; only 6% of
the eyes gained 3 lines, and 32% of the eyes gained
1 line. Preliminary results of intravitreal bevaci-
zumab have been published and seem to be promising
up to 1 year.8–15
We have published the first retrospective study with
the short-term results of intravitreous ranibizumab for
the treatment of myopic CNV.16 The 1-year results of
this study are presented herein.
Patients and Methods
Patients and methods were previously described.16
This prospective, nonrandomized, multicenter, inter-
ventional, case series included 32 patients with 34
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myopic eyes with CNV, from 2 countries (Portugal
and Spain), who had been followed-up and treated
with ranibizumab by 5 ophthalmologists (R.M.S.,
J.M.R.-M., P.R., A.C., and L.R.) in their clinical prac-
tice. The short-term results of 26 of these 34 eyes
already have been published.16
Thirteen eyes had previously undergone PDT at the
time of inclusion in the study, and 21 eyes had no
previous treatment. At baseline, all patients had evi-
dence, on fluorescein angiography (FA), of leakage
involving the fovea and potentially related with visual
acuity decrease. No additional PDT was performed in
any case during the follow-up. Inclusion and exclu-
sion criteria were as follows.
Inclusion Criteria
● Pathologic myopia with axial length 25 mm
and spherical equivalent 8 diopters
● Sub- or juxtafoveal CNV
● With or without previous PDT
● Visual acuity 20/400
● Age 21 years; signature required on a written
informed consent form
Exclusion Criteria
● CNV resulting from causes other than myopic
CNV, including ocular histoplasmosis syndrome,
angioid streaks, multifocal choroiditis, and cho-
roidal rupture
● Any retinal vasculopathies, including diabetic
retinopathy, retinal vein occlusions, etc., in the
study eye
● Previous treatment with other antiangiogenic
drugs (such as bevacizumab or pegaptanib), intra-
vitreal triamcinolone; or radiation; also, PDT
with Visudyne administered 3 months before
the inclusion
● Subfoveal or juxtafoveal laser scar
● Concomitant disease in the study eye, including
uveitis, presence of pigment epithelial tears or
rips, acute ocular or periocular infection, and
central serous chorioretinopathy
● Advanced glaucoma (0.8 cup-to-disk ratio) or
intraocular pressure 21 mmHg in the study eye
despite adequate treatment with medication
● Pregnancy or potential pregnancy (premeno-
pausal women not using adequate contraception)
All patients signed an informed consent form to
participate in this prospective study after a thorough
discussion of all their therapeutic options and after the
approval by the institutional review board of each
center. The study was performed in accordance with
the tenets of the Declaration of Helsinki.
A nonloading dose treatment regimen was assumed
in all participating centers. Eligible patients received a
baseline intravitreal injection of ranibizumab and were
assessed every 4 weeks thereafter. Clinical evaluation
after baseline included, in all cases, best-corrected
visual acuity (BCVA) using an Early Treatment Dia-
betic Retinopathy Study chart, ocular pressure, biomi-
croscopy, fundoscopy, optical coherence tomography
(OCT), and/or FA. The need for retreatment was de-
termined by the presence of intra- or subretinal fluid in
the 6 high-density, high-resolution radial diagonal
scans produced by OCT (Stratus OCT, version 4.0.2,
Carl Zeiss Meditec, Dublin, CA), metamorphopsia,
and/or FA subfoveal or juxtafoveal leakage. Intra-
vitreal injection of 0.5 mg of ranibizumab (Lucentis,
Novartis, Switzerland) in a 0.05-mL volume of solu-
tion was administered using a 30-gauge needle 4 mm
posterior to the limbus. The procedure was performed
on an outpatient basis under strict aseptic technique
and using topical anesthesia. Indirect ophthalmoscopy
was performed before the procedure in all cases. Pa-
tients were given topical ofloxacin, 4 times daily, 3
days before and 3 days after each injection.
Patients with recent thromboembolic events (6
months) were not usually injected with ranibizumab,
but the final decision was at the discretion of the
treating physician. A reevaluation of all the patients
was performed every 4 weeks after the first injection
of ranibizumab, including the presence of metamor-
phopsia, BCVA, slit-lamp evaluation, biomicroscopic
fundus examination, OCT, and/or FA. In doubtful
cases, FA was performed for deciding the necessity of
retreatment.
Measurements of visual acuity were performed at
all visits with an Early Treatment Diabetic Retinopa-
thy Study chart, and BCVA was obtained. Ocular
imaging consisted of FA (performed at baseline in all
cases and as needed during the follow-up) and/or OCT
at each follow-up visit. Although the automated mac-
ular thickness map was obtained with the fast-mode
low-density scans, central retinal thickness measure-
ments were determined from manual measurements in
high-density scans.
For statistical analysis, the Wilcoxon signed-rank test
and the two-tailed t-test were used, comparing changes
in BCVA and central retinal thickness on OCT. A P
value 0.05 was considered statistically significant.
Results
A total of 34 eyes (17 right eyes and 17 left eyes)
from 32 patients (20 women and 12 men; mean age,
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54 years; standard deviation, 17 years) were treated
with at least 1 injection of ranibizumab. Characteris-
tics of all the eyes studied are summarized in Tables 1
and 2.
A significant improvement in visual acuity occurred
at 3, 6, 9, and 12 months (P  0.001). Treated eyes
gained a mean of 8 letters at 12 months.
An improvement in visual acuity of 3 lines oc-
curred in 8 eyes (24%) at 1 year (Tables 1 and 2); 15
eyes (44%) improved 2 lines, 22 eyes (65%) im-
proved 1 line, and 27 eyes (79%) improved 0
letters. A decrease in visual acuity occurred in 7 eyes
(21%) and was inferior to 2 lines in all cases. None of
the treated eyes lost 3 Early Treatment Diabetic
Retinopathy Study lines (15 letters). No systemic or
ocular side effects were registered during the follow-
up. A mean of 3.6 treatments were performed during
the 12 months of follow-up.
Thirteen of the included eyes had undergone PDT
previously (1–6 treatments). No additional PDT was
performed after enrollment in the study. These 13 eyes
were compared with the 21 naïve-to-treatment eyes
regarding baseline characteristics (age, visual acuity,
and central macular thickness) and response to intra-
vitreal ranibizumab. No statistically significant differ-
ence (P  0.05) was found between the PDT group of
eyes and the non-PDT group of eyes regarding any of
the mentioned baseline characteristics, the posttreatment
number of letters gained or lost, or the number of treat-
ments. Macular thickness was significantly higher at 12
months in the eyes treated with PDT. The eyes previ-
ously treated with PDT improved a mean of 6 letters in
12 months, after a mean of 4.2 intravitreal injections, and
the difference was statistically significant compared with
baseline visual acuity (P 0.05) at 6, 9, and 12 months.
Eyes with no previous PDT improved an average of 9
letters at 12 months, after a mean of 3.2 intravitreal
injections; the difference was statistically significant at 3,
6, 9, and 12 months (P  0.01).
Central macular thickness, evaluated manually in
the high-density, high-resolution scans, decreased sig-
nificantly from baseline to 12 months of follow-up in
the full set of patients (P  0.01) and in the group of
naïve-to-treatment patients (P  0.001) but not in
those whose eyes underwent PDT previously (P 
0.05). None of the patients experienced systemic or
ocular complications including endophthalmitis, reti-
nal detachment, increased intraocular pressure, in-
traocular inflammation, or thromboembolic events.
Discussion
Ranibizumab is an antiangiogenic medication that
blocks the effects of vascular endothelial growth fac-
tor. The efficacy of ranibizumab in the treatment of
CNV caused by age-related macular degeneration is
well established, and in many countries, ranibizumab
is approved for this indication.17,18 Bevacizumab, an-
other antiangiogenic medication that similarly inhibits
vascular endothelial growth factor action, is widely
used for CNV caused by age-related macular degen-
eration but is not approved for this indication by any
regulatory body. In theory, the efficacy of both ranibi-
zumab and bevacizumab to cause regression of myo-
pic CNV should be similar to the efficacy they have in
causing regression of CNV caused by age-related
macular degeneration. Reports of the use of bevaci-
zumab in the treatment of myopic CNV have demon-
strated promising results, and several reports have
demonstrated bevacizumab to be superior to PDT with
verteporfin for CNV in myopia.8–15
We have demonstrated a short-term benefit of treat-
ment of myopic CNV with ranibizumab.16 Our 1-year
results of intravitreal ranibizumab in myopic eyes with
CNV confirm the short-term efficacy and safety re-
sults. The entire set of treated eyes lost 3 lines, and
79% of them showed no letter loss. Treated eyes
gained a mean of 8 letters at 12 months of follow-up,
and the difference was statistically significant com-
pared with baseline visual acuity.
Both eyes with and without previous PDT gained
vision (6 and 9 letters, respectively) at 12 months, and
the difference between the 2 groups was not signifi-
cant. However, some differences between them were
seen. The previous PDT group showed a significant
gain in visual acuity at 6, 9, and 12 months (P 0.05)
but not at 3 months; visual acuity loss occurred in 31%
of the cases; and only 8% achieved a visual acuity of
20/40, despite the significant improvement in mean
visual acuity and the reduction in cases with visual
acuity 20/200. Eyes with no previous PDT showed
a significant improvement in visual acuity at 3, 6, 9,
and 12 months (P  0.001); visual acuity loss oc-
curred only in 9% of the cases; the number of eyes
with 20/40 visual acuity doubled from 24% at base-
line to 48% at 12 months (Table 2); and the number of
eyes with visual acuity 20/200 decreased from 29%
to 10%. There are many possible explanations for the
relatively inferior results in eyes with previous PDT,
including choriocapillary atrophy resulting from PDT
and the simple fact that the previous PDT eyes prob-
ably would have a more aggressive CNV with a
poorer response to any treatment.
The relatively high percentage of eyes with some
visual acuity loss at 12 months (21%) may be related
to many factors, such as the nonloading dose regimen,
the criteria for retreatment mainly based in OCT, and
even the fact that eyes previously treated with PDT
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were also included (one-third of the eyes with pre-
vious PDT and only 9% of the eyes with no previous
PDT lost vision).
The mean number of treatments required in the
entire set of eyes was 3.6 at 12 months. The mean
number of injections was 1.9 in the first 3 months, 0.6
between 3 and 6 months, 0.5 between 6 and 9 months,
and 0.6 between 9 and 12 months. Our criteria for
retreatment was based on the presence of fluid ob-
served on OCT and/or leakage on FA and the presence
of metamorphopsia.16 A nonloading dose regimen was
adopted in all study centers. This decision was based
on the assumption that the greater improvement in
visual acuity is achieved after the first injection of
ranibizumab16,18 and the fact that CNV is generally
less extensive in myopic eyes than in eyes with age-
related macular degeneration. Myopic eyes with CNV,
in general, have less intra- and subretinal fluid, which
may contribute to a better response to intravitreal
ranibizumab. In fact, in our series, the greater im-
provement in visual acuity occurred after the first
injection (5 letters), whereas additional improvements
in visual acuity occurred at 6 and 9 months. At 3
months, 26 eyes (76%) had received 3 injections,
and at the 12-month evaluation, 11 eyes (32%) had
been treated with only2 injections. We believed that
the adoption of a loading-dose regimen would be
excessive and unnecessary. However, we could not
exclude the possibility that a greater improvement
would have been achieved with a more intense treat-
ment regimen.
A comparison between eyes gaining and losing
vision at 12 months showed no significant difference
regarding age, initial visual acuity, OCT central mac-
ular thickness, number of injections, or previous PDT
(P  0.05). Twenty-two eyes gained vision after the
first visit. Twenty of them (91%) maintained some
gain in visual acuity at 12 months. Seven eyes lost
vision after the first injection (cases 3, 10, 12, 15, 18,
23, and 25). Five of them (cases 3, 12, 15, 18, and 25)
lost 5 letters at 1 month and did not recover by the
12-month follow-up visit. The other 2 eyes lost 5
letters and gained additional visual acuity during the
follow-up. Eyes losing vision at the 1-month fol-
low-up (after the first treatment) had a worse progno-
sis. They had a much higher possibility of maintaining
a negative score at 12 months (P  0.001) compared
with eyes that initially showed some gain. These re-
sults suggested that the response to the first injection
may be a good predictor of efficacy.
No cases of endophthalmitis, stroke, or retinal de-
tachment were registered during the follow-up. Par-
ticular care was taken to observe the peripheral retina
before treatment, and prophylactic topical antibiotics
were administered before and after the injection.
Limitations of our study were related to its multicenter
and nonrandomized design. An effort was made to use
similar standardized procedures in the five centers. Pa-
tients were observed each month with clinical examina-
tion, BCVA assessment, and OCT (and FA, as needed).
Best-corrected visual acuity was obtained with Early
Treatment Diabetic Retinopathy Study charts, and the
score was registered. Even so, some bias may have been
introduced in the study. However, its potential impact
would have been minimal, considering that visual acuity
results are consistent and associated with anatomical
improvement that is confirmed by OCT. In fact, a sig-
nificant central macular thickness was registered at 12
months and was associated with significant improvement
in visual acuity.
In conclusion, the 1-year results of intravitreal ranibi-
zumab for myopic CNV using a routine clinical care
regimen were positive. Nearly one-fourth of the eyes
showed a significant improvement in visual acuity at 12
months, one-third of the eyes had vision that allowed
patients to drive or read, and no cases of severely de-
creased visual acuity were registered. Significant im-
provement in visual acuity also occurred in eyes with
Table 2. Eyes With and Without Previous PDT
VA With Previous PDT Without Previous PDT P
Initial VA (letters) 20/100 (49 letters) 53 letters (20/100) NS
12-month VA 20/80 (55 letters) 62 (20/63 letters) NS
Initial thickness 335 m 292 m NS
12-month thickness 326 m 222 m 0.01
VA gain at 12 months 6 letters 9 letters NS
Initial VA 20/40 1 (8%) 5 (24%) —
Final VA 20/40 1 (8%) 10 (48%) —
Initial VA 20/200 2 (15%) 6 (29%) —
Final VA 20/200 1 (8%) 2 (10%) —
Gain of 15 letters 3 (23%) 5 (24%) —
Loss of 5 letters 5 (38%) 2 (10%) —
VA, visual acuity; NS, not significant.
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previous PDT, although the results were less impressive.
Additional prospective long-term studies will be neces-
sary to evaluate the safety and efficacy of intravitreal
ranibizumab in the treatment of myopic CNV.
Key words: Lucentis, myopia, ranibizumab, anti-
angiogenic drugs, CNV, photodynamic therapy, verte-
porfin, bevacizumab.
References
1. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schep-
ens CL. Natural history of choroidal neovascularization in
degenerative myopia. Ophthalmology 1984;91:1573–1581.
2. Hampton GR, Kohen D, Bird AC. Visual prognosis of disci-
form degeneration in myopia. Ophthalmology 1983;90:923–
926.
3. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity
outcomes of patients 50 years of age and older with high
myopia and untreated choroidal neovascularization. Ophthal-
mology 1999;106:2063–2067.
4. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual
prognosis of choroidal neovascularization in high myopia: a
comparison between age groups. Ophthalmology 2002;109:
712–719.
5. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin
therapy of subfoveal choroidal neovascularisation in patho-
logic myopia: 2-year results of a randomized clinical trial—
VIP report no. 3. Ophthalmology 2003;110:667–673.
6. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic
therapy in highly myopic subfoveal choroidal neovascularisa-
tion. Br J Ophthalmol 2003;87:173–176.
7. Pece A, Vadala` M, Isola V, Matranga D. Photodynamic ther-
apy with verteporfin for juxtafoveal choroidal neovasculariza-
tion in pathologic myopia: a long-term follow-up study. Am J
Ophthalmol 200;143:449–454.
8. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety
and efficacy of intravitreal bevacizumab (Avastin) for neovas-
cular age-related macular degeneration. Retina 2006;26:495–
511.
9. Ikuno YH, Sayanagi K, Soga K, et al. Intravitreal bevacizumab
for choroidal neovascularization attributable to pathological
myopia: one-year results. Am J Ophthalmol 2009;147:94–100.
10. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz
J, et al. Short-term effects of intravitreal bevacizumab for
subfoveal choroidal neovascularization in pathologic myopia.
Retina 2007;27:707–712.
11. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravit-
reous bevacizumab to treat subfoveal choroidal neovascular-
ization in highly myopic eyes: short-term results. Eye (Lond)
2009;23:334–338.
12. Rosenfeld PJ. Intravitreal Avastin for choroidal neovasculari-
sation in pathological myopia: the controversy continues. Br J
Ophthalmol 2007;91:128–130.
13. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CA. Intravitreal
bevacizumab treatment for choroidal neovascularization in
pathologic myopia: 12-month results. Am J Ophthalmol 2009;
147:84–93.
14. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of
bevacizumab for choroidal neovascularisation associated with
pathological myopia. Br J Ophthalmol 2007;91:161–165.
15. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevaci-
zumab (Avastin) for myopic choroidal neovascularization.
Six-month results of a prospective pilot study. Ophthalmology
2007;114:2190–2196.
16. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term
efficacy and safety of intravitreal ranibizumab for myopic
choroidal neovascularisation. Retina 2008;28:1117–1123.
17. Tong JP, Chan WN, Liu DT, et al. Aqueous humor levels of
vascular endothelial growth factor and pigment epithelium-
derived factor in polypoidal choroidal vasculopathy and cho-
roidal neovascularization. Am J Ophthalmol 2006;141:456–
462.
18. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III
clinical trial results. Ophthalmol Clin North Am 2006;19:361–
372.
412 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES ● 2010 ● VOLUME 30 ● NUMBER 3
